Enclomiphene results: what the research actually shows

Last updated 2026-07-27

What is enclomiphene and how is it different from clomiphene?

Enclomiphene is one of the two isomers that make up clomiphene citrate, the older fertility drug. Clomiphene is actually a mixture of enclomiphene and zuclomiphene, roughly in a 62:38 ratio depending on the batch ^[1]. Enclomiphene is the trans-isomer and does most of the anti-estrogenic work at the hypothalamus. Zuclomiphene, the cis-isomer, is weakly estrogenic and lingers in the body far longer, with a half-life measured in weeks rather than days ^[2]. That matters because a lot of the side-effect reputation clomiphene carries, the mood changes, the visual disturbances some men report, gets pinned partly on zuclomiphene accumulation over repeated cycles. Enclomiphene, isolated from its mirror-image twin, was designed to give you the testosterone-raising effect without dragging along as much of the estrogenic baggage. That's the theory, and it's the reason a drug company spent over a decade trying to get it approved on its own. So when someone says "enclomiphene" they mean a single isomer. When they say "clomiphene" or "Clomid," they mean the mixture. Some men do fine on generic clomiphene at low doses. Enclomiphene is the more targeted version, at least on paper.

Is enclomiphene FDA-approved?

No. Enclomiphene citrate is not FDA-approved as a standalone medication for any indication. The branded version, Androxal, went through multiple Phase 3 trials under Repros Therapeutics in the 2010s and never made it to approval ^[3]. The FDA sent Repros a Complete Response Letter, and the company shelved the program rather than run the additional trials the agency wanted. What's sold today under names like Enclomiphene Direct is compounded enclomiphene citrate, made by a licensed compounding pharmacy under a prescription, not a mass-manufactured, FDA-approved drug. That's a real distinction with real consequences: compounded drugs aren't reviewed by the FDA for safety and efficacy the way approved drugs are, and formulations can vary between pharmacies ^[4]. If you're being told enclomiphene is FDA-approved, that's wrong, and it's worth asking your provider directly which pharmacy is filling the prescription and what their quality documentation looks like. This doesn't mean the drug lacks evidence. It means the evidence comes from academic and industry trials rather than from an approved label with FDA-vetted dosing instructions. You're relying on the published literature and your prescriber's judgment, not an FDA package insert.

What do the actual clinical trials show about testosterone levels?

The strongest data comes from the Phase 3 program for Androxal, published in the Journal of Sexual Medicine in 2016. Across two 12-week randomized, double-blind, placebo and testosterone-gel-controlled trials in men with secondary hypogonadism (low testosterone with low or inappropriately normal LH/FSH), enclomiphene 12.5 mg and 25 mg daily normalized serum testosterone in the majority of treated men ^[5]. In one of those trials, roughly 79-88% of men on enclomiphene reached normal testosterone levels (over 300 ng/dL) by week 6, comparable to the testosterone gel arm, while placebo response was far lower ^[5]. LH and FSH rose or stayed within normal range on enclomiphene, whereas they dropped sharply in the testosterone gel group. That's exactly what you'd expect, since exogenous testosterone shuts down the hypothalamic-pituitary-gonadal axis. Earlier dose-finding work, including a 2013 study by Kim et al. in the Journal of Sexual Medicine, and pharmacokinetic work from Kaminetsky and colleagues, showed similar direction of effect: enclomiphene raises total and free testosterone in men with low baseline levels, generally within the same 2 to 6 week window ^[6]. These are not massive trials by pharma standards, typically a few hundred men total across the program, and follow-up rarely extends past 3 to 6 months. That's the honest limitation: we have solid short-term data and much thinner long-term data.

Does enclomiphene actually preserve fertility, or is that theoretical?

The mechanism is well established, the long-term fertility outcome data is thinner than most marketing suggests. Enclomiphene works by blocking estrogen receptors in the hypothalamus, which the brain reads as "estrogen is low," so it increases GnRH pulses, which raises LH and FSH from the pituitary, which drives the testes to keep making testosterone and sperm . Exogenous testosterone does the opposite: it tells the hypothalamus estrogen and testosterone are both plenty high, GnRH and LH/FSH fall, and the testes downshift or shut down sperm production. In the Phase 3 enclomiphene trials, LH and FSH were maintained or increased, and testicular size and sperm parameters were not suppressed the way they are on injectable testosterone ^[5]. That's a meaningful and consistent finding across the studies. What's missing is a large, dedicated trial tracking actual pregnancy rates or sperm count changes over 12+ months in men using enclomiphene specifically for fertility purposes, the kind of data urologists would want before calling it a proven fertility treatment rather than a fertility-sparing one. The more honest framing: enclomiphene doesn't suppress the axis that testosterone production and spermatogenesis depend on. It doesn't guarantee improved fertility outcomes, and nobody has published the large randomized trial that would prove pregnancy rates go up. If fertility is your primary goal, this is a conversation for a reproductive urologist, and semen analysis before and during treatment is the only way to know what's actually happening in your case, not a hunch based on the mechanism.

How does enclomiphene compare to TRT for testosterone and fertility?

What are the actual side effects reported in enclomiphene studies?

In the Phase 3 trials, the most commonly reported adverse events with enclomiphene were headache, fatigue, and mild mood changes, occurring at rates broadly similar to or somewhat above placebo, though the trials were not large enough or long enough to catch rare events reliably ^[5]. Some men reported nausea or hot flush-type symptoms early in treatment. Because enclomiphene is a SERM, there's a theoretical class-level concern about visual disturbances, the kind reported more with clomiphene at higher or longer-duration dosing, though this appears less common with isolated enclomiphene given zuclomiphene is the isomer more implicated in that side effect profile ^[2]. Anyone who notices visual changes on any SERM should stop and call their prescriber, not wait it out. Lipid changes have shown up in some studies too; testosterone gel arms in the Phase 3 trials showed larger negative changes in HDL cholesterol compared to enclomiphene, which is a point in enclomiphene's favor if accurate, but it's based on a handful of trials, not a body of long-term cardiovascular outcome data ^[5]. Nobody has run a 5 or 10 year cardiovascular outcomes trial on enclomiphene. That kind of data simply doesn't exist yet for this drug, in either direction.

Who was studied in the enclomiphene trials, and does that match who's using it now?

The Phase 3 program enrolled men with secondary hypogonadism, meaning low testosterone paired with low or inappropriately normal LH/FSH, generally overweight or obese men in their 30s to 50s, since obesity is a major driver of secondary hypogonadism ^[5]. That's a fairly specific population. A lot of men buying compounded enclomiphene today are younger guys who want to avoid TRT's fertility tradeoffs, or men coming off anabolic steroid use looking to restart their own production, or men who simply prefer avoiding injections of exogenous hormone. Some of these use cases overlap reasonably well with the trial population; others, like post-steroid recovery, weren't part of the original trials at all and rest on extrapolation from the same HPG-axis mechanism rather than dedicated study data. If you have primary hypogonadism (testicular failure, high LH/FSH already), enclomiphene doesn't have the raw material to work with. Pushing GnRH harder does nothing if the testes themselves can't respond. That's a case where TRT is the appropriate route, not enclomiphene, and any provider worth using should be checking baseline LH, FSH, and total testosterone before prescribing either.

How is enclomiphene actually dosed in practice?

There is no FDA-approved label, so dosing comes from the trial protocols and prescriber experience rather than a standardized package insert. The Phase 3 trials tested 12.5 mg and 25 mg daily oral doses, with 25 mg generally producing a stronger testosterone response but also a slightly higher rate of mild side effects ^[5]. In practice, compounding pharmacies and prescribers vary. Some start men at 12.5 mg every other day, others at 25 mg daily, and titrate based on follow-up labs at 6 to 8 weeks. Since it's compounded, oral capsules are the most common form, but some providers use injectable protocols off-label, though the injectable route wasn't the format studied in the main trials. If you want the specifics on how a typical protocol is structured, see our Enclomiphene Direct dosage guide and the Enclomiphene Direct dosage calculator for working out a starting point based on labs. For anyone using an injectable formulation, how to reconstitute Enclomiphene Direct, Enclomiphene Direct how to inject, and Enclomiphene Direct injection sites cover the practical mechanics. Cycle duration is its own question, and it's addressed separately in Enclomiphene Direct cycle length, since the trials only ran 12 weeks and real-world use often extends longer under lab monitoring.

How long does it take to see results, and how is response measured?

In the Phase 3 trials, testosterone increases showed up early, with a meaningful share of men reaching normal range (above 300 ng/dL) by week 6, and effects sustained through the 12-week trial period ^[5]. That's faster than some men expect; it's not a slow-build supplement, it's an active hormonal signal to the pituitary. Response is measured with blood work, not symptoms alone: total and free testosterone, LH, FSH, and sometimes estradiol, drawn before starting and again at 6 to 8 weeks. Symptom improvement (energy, libido, mood) often lags the lab numbers by a few weeks, and some men feel little subjective difference even with normalized testosterone, which is a known disconnect in hypogonadism treatment generally, not unique to enclomiphene. If labs at 6-8 weeks don't show a meaningful rise, that's a real signal to reassess. Either the dose is too low, the underlying cause of low testosterone isn't primarily hypothalamic-pituitary in nature, or the compounded formulation's potency needs checking with the pharmacy. Non-responders exist in every trial arm; the ~80-90% response figures mean a meaningful minority didn't normalize on enclomiphene alone ^[5].

What does Enclomiphene Direct's provider-reviewed model add here?

Enclomiphene Direct's role is connecting men with a licensed prescriber who reviews labs and history, then, if appropriate, writes a prescription that's filled by a licensed compounding pharmacy partner. Enclomiphene Direct itself doesn't compound or manufacture the medication; it coordinates the provider review and the pharmacy fulfillment side of getting a legitimate prescription filled. That distinction matters given everything above: since enclomiphene isn't FDA-approved as a standalone drug, the two things actually protecting you are a prescriber who checks your baseline hormone panel and follows up with repeat labs, and a compounding pharmacy that's licensed and inspected. A provider-reviewed pathway with baseline and follow-up labs is the responsible way to use a drug that doesn't have an FDA-approved label to fall back on.

What are the real gaps and unanswered questions in the research?

Be honest about what's not known. There is no large published trial tracking actual pregnancy rates in couples where the male partner used enclomiphene, only surrogate markers like LH, FSH, and testicular size ^[5]. There's no long-term (multi-year) cardiovascular or bone density outcome data specific to enclomiphene the way there is, imperfectly, for testosterone therapy. There's no head-to-head trial comparing enclomiphene against low-dose hCG monotherapy or against clomiphene citrate itself in the same population, despite all three being used somewhat interchangeably in practice. Because it's compounded rather than FDA-approved, there's also no standardized bioequivalence data confirming that capsules from different compounding pharmacies deliver comparable blood levels, the way generic-to-brand bioequivalence testing works for approved drugs ^[4]. That's a real, practical gap, more than an academic one: it's a reason to stick with a pharmacy that does third-party potency testing and to recheck labs after starting, rather than assuming the dose on the label matches what your body sees.

Frequently asked questions

Is enclomiphene the same thing as clomiphene?

No. Clomiphene citrate is a mixture of two isomers, enclomiphene (about 62%) and zuclomiphene (about 38%) ^[1]. Enclomiphene is the isolated trans-isomer, thought to drive most of the testosterone-raising effect with less of the long-lingering estrogenic activity zuclomiphene carries. They're related but not interchangeable in composition.

Is enclomiphene FDA-approved for low testosterone?

No. The branded version, Androxal, went through Phase 3 trials but never received FDA approval; the program was shelved after a Complete Response Letter ^[3]. What's available today is compounded enclomiphene citrate from a licensed compounding pharmacy under prescription, not an FDA-approved, mass-manufactured drug.

Does enclomiphene preserve fertility better than TRT?

Trial data shows enclomiphene maintains or raises LH and FSH and doesn't suppress testicular size the way injectable testosterone does ^[5][7]. That's a real mechanistic advantage for men who want to keep their own hormone production running. It's not proof of improved pregnancy rates, since no large trial has tracked that outcome directly.

How much does enclomiphene raise testosterone?

In Phase 3 trials, roughly 79-88% of men with secondary hypogonadism reached normal testosterone (above 300 ng/dL) by week 6 on enclomiphene 12.5-25 mg daily, similar to the testosterone gel comparator arm ^[5]. Individual response varies and depends on baseline levels and the underlying cause of low testosterone.

What's the difference between primary and secondary hypogonadism for enclomiphene candidates?

Secondary hypogonadism means low testosterone with low or inappropriately normal LH/FSH, meaning the pituitary/hypothalamus signal is weak; this is the population enclomiphene trials studied and where it can work ^[5]. Primary hypogonadism means the testes themselves have failed, with high LH/FSH already; enclomiphene has little to work with there, and TRT is the appropriate route.

What side effects showed up in enclomiphene trials?

Reported adverse events in Phase 3 trials included headache, fatigue, and mild mood changes, generally similar to or somewhat above placebo rates ^[5]. Visual disturbances, more associated with zuclomiphene in clomiphene use, appear less commonly with isolated enclomiphene, though large-scale, long-term safety data doesn't yet exist for either finding.

How long does it take enclomiphene to work?

In the Phase 3 trials, meaningful testosterone increases appeared by week 6, with effects maintained through the 12-week study period ^[5]. Follow-up labs at 6 to 8 weeks are the standard way to check response; symptom improvement can lag lab normalization by several weeks.

Can enclomiphene be used after anabolic steroid use to restart natural testosterone production?

It's used this way off-label based on its HPG-axis mechanism, but this wasn't the population studied in the Phase 3 trials, which enrolled men with secondary hypogonadism from causes like obesity, not steroid-induced suppression. It's a reasonable mechanistic extrapolation, not a dedicated evidence base.

Does insurance cover enclomiphene?

Rarely, since it's compounded rather than FDA-approved, most insurance plans don't cover it the way they might cover approved testosterone products. Coverage and cash pricing vary by provider and pharmacy; ask directly what a compounded prescription costs out of pocket before starting.

Is compounded enclomiphene safe if it isn't FDA-approved?

Compounded medications are prepared by licensed pharmacies under state and federal oversight, but they don't go through the FDA's premarket review for safety and efficacy that approved drugs do ^[4]. Using a pharmacy with third-party potency testing and working with a prescriber who orders baseline and follow-up labs are the main ways to manage that gap.

What labs should I get before and during enclomiphene treatment?

Baseline labs typically include total and free testosterone, LH, FSH, and estradiol, repeated at 6 to 8 weeks to check response, per the monitoring approach used in the Phase 3 trials ^[5]. Men focused on fertility should also discuss semen analysis with their prescriber or a reproductive urologist.

Does enclomiphene shrink the testicles like TRT can?

Trial data shows enclomiphene generally preserves testicular size because it maintains LH and FSH signaling rather than suppressing it, unlike exogenous testosterone which frequently causes testicular shrinkage over months of use ^[5][7]. Long-term data beyond the 12-week trial period is still limited.

Sources

1. NCBI Bookshelf/StatPearls, Clomiphene: Clomiphene citrate is a mixture of enclomiphene and zuclomiphene isomers
2. PubMed, pharmacokinetics of clomiphene isomers: Zuclomiphene has a much longer half-life than enclomiphene and accumulates with repeated dosing
3. FDA, Drugs@FDA database search for Androxal/enclomiphene: No enclomiphene product (Androxal) has received FDA approval
4. Journal of Sexual Medicine, Phase 3 enclomiphene trials (Kaminetsky et al., 2016): Enclomiphene normalized testosterone in the majority of hypogonadal men while preserving LH/FSH, versus suppression seen with testosterone gel
5. Journal of Sexual Medicine, Kim et al. dose-finding study: Early dose-finding studies showed enclomiphene raises total and free testosterone in hypogonadal men
6. Endocrine Society / Endotext, Male Hypogonadism chapter: Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and spermatogenesis, unlike agents that stimulate endogenous LH/FSH